학술논문
전자자료 공정이용 안내
우리 대학 도서관에서 구독·제공하는 모든 전자자료(데이터베이스, 전자저널, 전자책 등)는 국내외 저작권법과 출판사와의 라이선스 계약에 따라 엄격하게 보호를 받고 있습니다.
전자자료의 비정상적 이용은 출판사로부터의 경고, 서비스 차단, 손해배상 청구 등 학교 전체에 심각한 불이익을 초래할 수 있으므로, 아래의 공정이용 지침을 반드시 준수해 주시기 바랍니다.
공정이용 지침
- 전자자료는 개인의 학습·교육·연구 목적의 비영리적 사용에 한하여 이용할 수 있습니다.
- 합리적인 수준의 다운로드 및 출력만 허용됩니다. (일반적으로 동일 PC에서 동일 출판사의 논문을 1일 30건 이하 다운로드할 것을 권장하며, 출판사별 기준에 따라 다를 수 있습니다.)
- 출판사에서 제공한 논문의 URL을 수업 관련 웹사이트에 게재할 수 있으나, 출판사 원문 파일 자체를 복제·배포해서는 안 됩니다.
- 본인의 ID/PW를 타인에게 제공하지 말고, 도용되지 않도록 철저히 관리해 주시기 바랍니다.
불공정 이용 사례
- 전자적·기계적 수단(다운로딩 프로그램, 웹 크롤러, 로봇, 매크로, RPA 등)을 이용한 대량 다운로드
- 동일 컴퓨터 또는 동일 IP에서 단시간 내 다수의 원문을 집중적으로 다운로드하거나, 전권(whole issue) 다운로드
- 저장·출력한 자료를 타인에게 배포하거나 개인 블로그·웹하드 등에 업로드
- 상업적·영리적 목적으로 자료를 전송·복제·활용
- ID/PW를 타인에게 양도하거나 타인 계정을 도용하여 이용
- EndNote, Mendeley 등 서지관리 프로그램의 Find Full Text 기능을 이용한 대량 다운로드
- 출판사 콘텐츠를 생성형 AI 시스템에서 활용하는 행위(업로드, 개발, 학습, 프로그래밍, 개선 또는 강화 등)
위반 시 제재
- 출판사에 의한 해당 IP 또는 기관 전체 접속 차단
- 출판사 배상 요구 시 위반자 개인이 배상 책임 부담
'학술논문'
에서 검색결과 343건 | 목록
1~20
Academic Journal
Chen N; Cancer Center, the First Hospital of Jilin University, Changchun, China.; Pu C; Innovative Cellular Therapeutics Co, Ltd, Shanghai, China.; Zhao L; Cancer Center, the First Hospital of Jilin University, Changchun, China.; Li W; Cancer Center, the First Hospital of Jilin University, Changchun, China.; Wang C; Cancer Center, the First Hospital of Jilin University, Changchun, China.; Zhu R; Innovative Cellular Therapeutics Co, Ltd, Shanghai, China.; Liang T; Cancer Center, the First Hospital of Jilin University, Changchun, China.; Niu C; Cancer Center, the First Hospital of Jilin University, Changchun, China.; Huang X; Innovative Cellular Therapeutics Co, Ltd, Shanghai, China.; Tang H; Innovative Cellular Therapeutics Co, Ltd, Shanghai, China.; Wang Y; Cancer Center, the First Hospital of Jilin University, Changchun, China.; Yang H; Innovative Cellular Therapeutics Co, Ltd, Shanghai, China.; Jia B; Innovative Cellular Therapeutics Co, Ltd, Shanghai, China.; Jiang X; Innovative Cellular Therapeutics Co, Ltd, Shanghai, China.; Han G; Innovative Cellular Therapeutics Co, Ltd, Shanghai, China.; Wang W; Innovative Cellular Therapeutics Co, Ltd, Shanghai, China.; Chen D; Innovative Cellular Therapeutics Co, Ltd, Shanghai, China.; Wang Y; Innovative Cellular Therapeutics Co, Ltd, Shanghai, China.; Rowinsky EK; Innovative Cellular Therapeutics Inc, Rockville, Maryland.; Kennedy E; 80 Horseshoe Pt, Phoenixville, Pennsylvania.; Lu VX; Innovative Cellular Therapeutics Inc, Rockville, Maryland.; Cui G; Cancer Center, the First Hospital of Jilin University, Changchun, China.; Wu Z; Innovative Cellular Therapeutics Co, Ltd, Shanghai, China.; Xiao L; Innovative Cellular Therapeutics Inc, Rockville, Maryland.; Cui J; Cancer Center, the First Hospital of Jilin University, Changchun, China.
Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE
Academic Journal
Musher BL; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA. Electronic address: blmusher@bcm.edu.; Rowinsky EK; Lokon Pharma AB, Uppsala, Sweden.; Smaglo BG; University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Abidi W; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.; Othman M; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.; Patel K; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.; Jawaid S; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.; Jing J; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.; Brisco A; USF Health Morsani College of Medicine, Tampa, FL, USA.; Leen AM; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.; Wu M; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.; Sandin LC; Lokon Pharma AB, Uppsala, Sweden.; Wenthe J; Lokon Pharma AB, Uppsala, Sweden; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.; Eriksson E; Lokon Pharma AB, Uppsala, Sweden; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.; Ullenhag GJ; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden; Department of Oncology, Uppsala University Hospital, Akademiska Sjukhuset, Uppsala, Sweden.; Grilley B; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.; Leja-Jarblad J; Lokon Pharma AB, Uppsala, Sweden.; Hilsenbeck SG; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.; Brenner MK; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.; Loskog ASI; Lokon Pharma AB, Uppsala, Sweden; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Academic Journal
Rowinsky EK; Vivolux AB, Uppsala Science Park, c/o NEXTTOBE AB, Dag Hammarskjölds väg 40c, SE-751 83, Uppsala, Sweden. erowinsky@oncodrugs.com.; Paner A; Division of Hematology, Department of Internal Medicine, Rush University Cancer Center, Chicago, IL, USA.; Berdeja JG; Division of Hematology and Oncology, Sarah Cannon Research Institute, Nashville, TN, USA.; Paba-Prada C; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Venugopal P; Division of Hematology, Department of Internal Medicine, Rush University Cancer Center, Chicago, IL, USA.; Porkka K; Hematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland.; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.; Gullbo J; Vivolux AB, Uppsala Science Park, c/o NEXTTOBE AB, Dag Hammarskjölds väg 40c, SE-751 83, Uppsala, Sweden.; Linder S; Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.; Department of Medical and Health Sciences, University of Linköping, Linköping, Sweden.; Loskog A; Vivolux AB, Uppsala Science Park, c/o NEXTTOBE AB, Dag Hammarskjölds väg 40c, SE-751 83, Uppsala, Sweden.; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.; Richardson PG; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Landgren O; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE
Academic Journal
Academic Journal
Wakelee HA; Takimoto CH; Lopez-Anaya A; Chu Q; Middleton G; Dunlop D; Ramlau R; Leighl N; Rowinsky EK; Hao D; Zatloukal P; Jacobs CD; Rodon J
Academic Journal
Hammond-Thelin LA; Thomas MB; Iwasaki M; Abbruzzese JL; Lassere Y; Meyers CA; Hoff P; de Bono J; Norris J; Matsushita H; Mita A; Rowinsky EK
Investigational New Drugs; Feb2012, Vol. 30 Issue 1, p316-326, 11p
Academic Journal
Guttman-Yassky E; Mita A; De Jonge M; Matthews L; McCarthy S; Iwata KK; Verweij J; Rowinsky EK; Krueger JG
Academic Journal
Academic Journal
Spratlin JL; Cohen RB; Eadens M; Gore L; Camidge DR; Diab S; Leong S; O'Bryant C; Chow LQ; Serkova NJ; Meropol NJ; Lewis NL; Chiorean EG; Fox F; Youssoufian H; Rowinsky EK; Eckhardt SG; Spratlin, Jennifer L; Cohen, Roger B; Eadens, Matthew
Academic Journal
Baker LH; Rowinsky EK; Mendelson D; Humerickhouse RA; Knight RA; Qian J; Carr RA; Gordon GB; Demetri GD
Academic Journal
Mita MM; Mita AC; Chu QS; Rowinsky EK; Fetterly GJ; Goldston M; Patnaik A; Mathews L; Ricart AD; Mays T; Knowles H; Rivera VM; Kreisberg J; Bedrosian CL; Tolcher AW
Academic Journal
Sparreboom A; Wolff AC; Mathijssen RH; Chatelut E; Rowinsky EK; Verweij J; Baker SD; Sparreboom, Alex; Wolff, Antonio C; Mathijssen, Ron H J; Chatelut, Etienne; Rowinsky, Eric K; Verweij, Jaap; Baker, Sharyn D
Academic Journal
Chu QS; Schwartz G; de Bono J; Smith DA; Koch KM; Versola MJ; Pandite L; Arya N; Curtright J; Fleming RA; Ho PT; Rowinsky EK; Chu, Quincy S C; Schwartz, Garry; de Bono, Johann; Smith, Deborah A; Koch, Kevin M; Versola, Melissa J; Pandite, Lini; Arya, Nikita
Academic Journal
Academic Journal
Patient Care (Print); 2/28/1998, Vol. 32 Issue 4, p42-52, 5p
Academic Journal
Academic Journal
Frolova O; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Benito J; Brooks C; Wang RY; Korchin B; Rowinsky EK; Cortes J; Kantarjian H; Andreeff M; Frankel AE; Konopleva M
Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE
Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer.
Academic Journal
검색 결과 제한하기
제한된 항목
[AR] Rowinsky EK
발행연도 제한
-
학술DB(Database Provider)
저널명(출판물, Title)
출판사(Publisher)
자료유형(Source Type)
주제어
언어